Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INMB INmune Bio	$6.87 -14.3%	$7.54	$4.32 ▼ $10.50	$176.98M	1.55	295,248 shs	1.74 million shs
LRMR Larimar Therapeutics	$2.69 -6.9%	$2.25	$1.61 ▼ $11.20	$184.40M	0.79	810,009 shs	701,665 shs
MRSN Mersana Therapeutics	$0.35 -7.0%	$0.36	$0.26 ▼ $2.83	$45.76M	0.83	2.63 million shs	1.44 million shs
NLTX Neoleukin Therapeutics	$18.97 -4.0%	$16.06	$2.03 ▼ $14.36	$178.28M	1.11	50,104 shs	158,209 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INMB INmune Bio	-14.34%	-12.82%	-12.60%	-17.33%	-17.03%
LRMR Larimar Therapeutics	-6.92%	-7.56%	+35.86%	+4.67%	-66.33%
MRSN Mersana Therapeutics	-6.98%	-13.17%	+3.91%	-23.01%	-82.68%
NLTX Neoleukin Therapeutics	-4.00%	-4.72%	+5.45%	+19.68%	-55.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INMB INmune Bio	2.0804 of 5 stars	3.6	0.0	0.0	0.0	3.3	1.7	0.6
LRMR Larimar Therapeutics	2.6118 of 5 stars	3.6	3.0	0.0	0.0	3.4	1.7	0.0
MRSN Mersana Therapeutics	4.1118 of 5 stars	3.5	4.0	0.0	4.1	1.6	2.5	0.0
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INMB INmune Bio	3.17	Buy	$22.80	231.88% Upside
LRMR Larimar Therapeutics	3.11	Buy	$19.67	631.10% Upside
MRSN Mersana Therapeutics	3.00	Buy	$5.20	1,371.42% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MRSN, NLTX, LRMR, and INMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/16/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
5/16/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/15/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$3.00
5/6/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$4.00 ➝ $3.00
3/25/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/25/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00 ➝ $26.00
3/25/2025	LRMR Larimar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $16.00
3/25/2025	LRMR Larimar Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$13.00 ➝ $10.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INMB INmune Bio	$10K	15,787.26	N/A	N/A	$1.45 per share	4.74
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$2.69 per share	N/A
MRSN Mersana Therapeutics	$40.50M	1.09	N/A	N/A	($0.08) per share	-4.42
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INMB INmune Bio	-$42.08M	-$1.93	N/A	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)
LRMR Larimar Therapeutics	-$80.60M	-$1.49	N/A	N/A	N/A	N/A	-52.48%	-46.08%	8/6/2025 (Estimated)
MRSN Mersana Therapeutics	-$69.19M	-$0.59	N/A	N/A	N/A	-217.63%	-990.16%	-48.87%	8/12/2025 (Estimated)
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	∞	N/A	N/A	-37.22%	-30.91%	N/A

Latest MRSN, NLTX, LRMR, and INMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	MRSN Mersana Therapeutics	-$0.21	-$0.19	+$0.02	-$0.19	$6.05 million	$2.75 million
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
4/30/2025	Q1 2025	LRMR Larimar Therapeutics	-$0.42	-$0.46	-$0.04	-$0.46	N/A	N/A
3/27/2025	Q4 2024	INMB INmune Bio	-$0.54	-$0.40	+$0.14	-$0.40	N/A	N/A
3/24/2025	Q4 2024	LRMR Larimar Therapeutics	-$0.29	-$0.45	-$0.16	-$0.45	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INMB INmune Bio	N/A	2.59	2.59
LRMR Larimar Therapeutics	N/A	13.10	13.10
MRSN Mersana Therapeutics	13.35	2.35	2.35
NLTX Neoleukin Therapeutics	N/A	15.33	15.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INMB INmune Bio	12.72%
LRMR Larimar Therapeutics	91.92%
MRSN Mersana Therapeutics	93.92%
NLTX Neoleukin Therapeutics	52.37%

Insider Ownership

Company	Insider Ownership
INMB INmune Bio	35.70%
LRMR Larimar Therapeutics	4.50%
MRSN Mersana Therapeutics	13.00%
NLTX Neoleukin Therapeutics	1.58%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INMB INmune Bio	10	22.98 million	14.78 million	Optionable
LRMR Larimar Therapeutics	30	64.03 million	61.15 million	Optionable
MRSN Mersana Therapeutics	150	124.63 million	108.43 million	Optionable
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data

MRSN, NLTX, LRMR, and INMB Headlines

Recent News About These Companies

Neoleukin Therapeutics (NASDAQ:NLTX) Stock Price Down 4.8% - Time to Sell?

June 10, 2025 | marketbeat.com

Neoleukin Therapeutics (NASDAQ:NLTX) Trading 27.3% Higher - What's Next?

May 19, 2025 | marketbeat.com

(NGNE) Proactive Strategies

October 18, 2024 | news.stocktradersdaily.com

Neurogene concludes merger deal with Neoleukin Therapeutics

December 20, 2023 | pharmaceutical-technology.com

Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?

December 20, 2023 | finance.yahoo.com

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

December 15, 2023 | finance.yahoo.com

Neoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and Dates

December 4, 2023 | benzinga.com

Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…

October 5, 2023 | markets.businessinsider.com

Neoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

September 26, 2023 | finanznachrichten.de

Neoleukin Thera (NASDAQ: NLTX) should be up 500% - it’s actually up 7%

September 26, 2023 | dhakatribune.com

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

September 22, 2023 | finance.yahoo.com

Investing in Neoleukin Therapeutics Inc. [NLTX]: What You Must Know

August 21, 2023 | knoxdaily.com

Neoleukin Therapeutics Recent Insider Activity

August 18, 2023 | benzinga.com

BAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics Inc

August 18, 2023 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCU

August 8, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTX

August 1, 2023 | markets.businessinsider.com

Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc

July 28, 2023 | finance.yahoo.com

Moore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law Firm

July 26, 2023 | benzinga.com

Analysts review Neoleukin Therapeutics Inc.’s rating

July 26, 2023 | knoxdaily.com

ALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, NLTX, HCCI, CCF

July 24, 2023 | kentuckytoday.com

Baker Bros. Advisors Now Owns 19.99% of Neoleukin Therapeutics

July 24, 2023 | 247wallst.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRSN, NLTX, LRMR, and INMB Company Descriptions

INmune Bio NASDAQ:INMB

$6.87 -1.15 (-14.34%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$6.86 -0.01 (-0.15%)

As of 04:48 AM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Larimar Therapeutics NASDAQ:LRMR

$2.69 -0.20 (-6.92%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$2.70 +0.01 (+0.37%)

As of 04:45 AM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Mersana Therapeutics NASDAQ:MRSN

$0.35 -0.03 (-6.98%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$0.37 +0.01 (+4.13%)

As of 04:39 AM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Neoleukin Therapeutics NASDAQ:NLTX

$18.97 -0.79 (-4.00%)

As of 06/16/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time